Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin–piperaquine or artesunate–amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial

Makenga, Geofrey; Baraka, Vito; Francis, Filbert; Nakato, Swabra; Gesase, Samwel; Mtove, George; Madebe, Rashid; Kyaruzi, Edna; Minja, Daniel T. R.; Lusingu, John; Geertruyden, Jean-Pierre Van

doi:10.1016/s2214-109x(23)00204-8

Cited by 6 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Speaking of which, we also focused on dihydroartemisinin in particular for its rather productive research both in autoimmune diseases and in malaria. As an already well‐recognized antimalaria drug, although no clinical studies related to autoimmune diseases exist yet based on our research methods, dihydroartemisinin has gone through considerable clinical trials related to malaria, especially in vulnerable groups such as randomized controlled trials in pregnancy patients on the Thailand‐Myanmar border 124 and schoolchildren in Tanzania 125 . These clinical trials confirmed not only the satisfactory therapeutic effect, but more importantly, therapy of dihydroartemisinin led only acceptable mild adverse events and no treatment‐related serious adverse events or deaths which gave us hope in its clinical translation on autoimmune diseases.…”

Section: Summary and Future Prospectsmentioning

confidence: 99%

Artemisinins: Promising drug candidates for the treatment of autoimmune diseases

Gao,

Lin,

Wang

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Autoimmune diseases are characterized by the immune system's attack on one's own tissues which are highly diverse and diseases differ in severity, causing damage in virtually all human systems including connective tissue (e.g., rheumatoid arthritis), neurological system (e.g., multiple sclerosis) and digestive system (e.g., inflammatory bowel disease). Historically, treatments normally include pain‐killing medication, anti‐inflammatory drugs, corticosteroids, and immunosuppressant drugs. However, given the above characteristics, treatment of autoimmune diseases has always been a challenge. Artemisinin is a natural sesquiterpene lactone initially extracted and separated from Chinese medicine Artemisia annua L., which has a long history of curing malaria. Artemisinin's derivatives such as artesunate, dihydroartemisinin, artemether, artemisitene, and so forth, are a family of artemisinins with antimalarial activity. Over the past decades, accumulating evidence have indicated the promising therapeutic potential of artemisinins in autoimmune diseases. Herein, we systematically summarized the research regarding the immunoregulatory properties of artemisinins including artemisinin and its derivatives, discussing their potential therapeutic viability toward major autoimmune diseases and the underlying mechanisms. This review will provide new directions for basic research and clinical translational medicine of artemisinins.

show abstract

Section: Summary and Future Prospectsmentioning

confidence: 99%